![conference banner](/images/conference-banner.jpeg)
Abstract
This short review outlines the scientific progression from the neuropeptide vasoactive intestinal peptide as a neuroprotective agent that acts through glial cells to increase and modulate the synthesis and secretion of novel neuroprotective substances. Recent development in the studies on activity-dependent neuroprotective protein (ADNP) and activitydependent neurotrophic factor (ADNF) and short peptide derivatives of these proteins, ADNF-9 and NAP suggest that these peptides are neurotrophic and promote neurite outgrowth. These short peptides hold promise in future neuroprotective/ neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc.
Keywords: Vasoactive intestinal peptide (VIP), ciliary neurotrophic factor (CNTF), ADNF-9, neuroprotective, expression
Current Alzheimer Research
Title: Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate
Volume: 3 Issue: 3
Author(s): Illana Gozes and Irit Spivak-Pohis
Affiliation:
Keywords: Vasoactive intestinal peptide (VIP), ciliary neurotrophic factor (CNTF), ADNF-9, neuroprotective, expression
Abstract: This short review outlines the scientific progression from the neuropeptide vasoactive intestinal peptide as a neuroprotective agent that acts through glial cells to increase and modulate the synthesis and secretion of novel neuroprotective substances. Recent development in the studies on activity-dependent neuroprotective protein (ADNP) and activitydependent neurotrophic factor (ADNF) and short peptide derivatives of these proteins, ADNF-9 and NAP suggest that these peptides are neurotrophic and promote neurite outgrowth. These short peptides hold promise in future neuroprotective/ neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc.
Export Options
About this article
Cite this article as:
Gozes Illana and Spivak-Pohis Irit, Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate, Current Alzheimer Research 2006; 3 (3) . https://dx.doi.org/10.2174/156720506777632790
DOI https://dx.doi.org/10.2174/156720506777632790 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Skeletal Muscle in Motor Neuron Diseases: Therapeutic Target and Delivery Route for Potential Treatments
Current Drug Targets Stem Cells with Neurogenic Potential and Steroid Hormones
Current Topics in Medicinal Chemistry Cation-Responsive MRI Contrast Agents Based on Gadolinium(III)
Current Inorganic Chemistry (Discontinued) Targets of Anti-glucocorticoid Therapy for Stress-related Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Oxidation of Potassium Channels in Neurodegenerative Diseases: A Mini- Review
CNS & Neurological Disorders - Drug Targets Therapeutic Potential and Mechanisms of Action of Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome
Current Stem Cell Research & Therapy Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) AMPA Receptor Potentiators: Application for Depression and Parkinsons Disease
Current Drug Targets Editorial [Hot Topic: Sigma Receptor Research: Progress Towards Diagnostic and Therapeutic Uses of Sigma Ligands (Executive Guest Editor: Carmen Abate )]
Current Pharmaceutical Design The Heat Shock Connection of Metabolic Stress and Dietary Restriction
Current Pharmaceutical Biotechnology Brain Nitric Oxide and Its Dual Role in Neurodegeneration / Neuroprotection: Understanding Molecular Mechanisms to Devise Drug Approaches
Current Medicinal Chemistry Tau Protein Aggregation in Alzheimer's Disease: Recent Advances in the Development of Novel Therapeutic Agents
Current Pharmaceutical Design Neuroprotection: The Emerging Concept of Restorative Neural Stem Cell Biology for the Treatment of Neurodegenerative Diseases
Current Neuropharmacology Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Nanomedicine and its Application in Treatment of Microglia-mediated Neuroinflammation
Current Medicinal Chemistry Cdk5 in the Adult Non-Demented Brain
Current Drug Targets - CNS & Neurological Disorders Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Pathologically-Activated Therapeutics for Neuroprotection: Mechanism of NMDA Receptor Block by Memantine and S-Nitrosylation
Current Drug Targets Copy Number Variants in Neurological Disorder
Current Genomics Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design